Opportunity Analysis Clostridium difficile Infections and Forecasts to 2026
"The Report
OpportunityAnalyzer: Clostridium difficile Infections - Opportunity
Analysis and Forecasts to 2026 provides information on pricing,
market analysis, shares, forecast, and company profiles for key
industry participants. - MarketResearchReports.biz"
About
Clostridium
difficile Infections
Market
Clostridium difficile, a
Gram-positive, spore-forming, toxin-producing, non-invasive,
anaerobic bacterium, is the causative organism of C. difficile
infection (CDI), which is commonly associated with colitis, as well
as C. difficile-associated diarrhea (CDAD. CDIs begin with
colonization of the intestinal tract with C. difficile through
community-acquired or healthcare-associated means. Observed most
frequently in healthcare settings, CDIs often occur when normal
intestinal flora are disrupted by antibiotic administration, which
can give C. difficile a competitive growth advantage if patients are
exposed to the pathogen. Since 2000, CDIs have become more frequent,
more severe, more difficult to treat using existing therapies, and
more likely to recur than previously described. These realities,
along with increasing threat of antibiotic resistance, underscore the
importance of developing CDI-specific therapies and bringing them to
market.
Get Sample copy of this Report
@ https://www.marketresearchreports.biz/sample/sample/1350130
During the 10-year forecast
period, there are nine products that are on track to launch,
contributing to significant growth within the market. The launch of
the first prophylactic options for the prevention of CDIs, beginning
with Sanofi Pasteurs vaccine ACAM-CDIFF in 2019, will fulfill a major
unmet need, and will have a significant effect on the overall size of
the CDI market. The expected launch of the first microbiologic
therapies, leveraging the efficacy associated with FMT with respect
to CDI recurrence rates, will also have an effect on the overall
treatment landscape during the forecast period. In 2026, antibiotics
are expected to have remained the highest grossing product class in
the CDI market, with novel vaccines also contributing a significant
market share.
Scope
- Overview of CDI, including
epidemiology, etiology, pathophysiology, symptoms, diagnosis, and
current management strategies.
- Topline CDI market revenue from
2016-2026. Annual cost of therapy (ACOT) and major pipeline product
sales in this forecast period are included.
-
Key topics covered include current
treatment options, unmet needs and opportunities, and the drivers and
barriers affecting CDI therapeutics and prophylactics sales in the
7MM.
- Pipeline analysis: comprehensive
data split across different phases, emerging novel trends under
development, synopses of innovative early-stage projects, and
detailed analysis of late-stage pipeline products.
- Analysis of the current and
future market competition in the global CDI therapeutics and
prophylactics market. Insightful review of the key industry drivers,
restraints and challenges. Each trend is independently researched to
provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to -
- Develop and design your
in-licensing and out-licensing strategies through a review of
pipeline products and technologies, and by identifying the companies
with the most robust pipeline.
- Develop business strategies by
understanding the trends shaping and driving the global CDI
therapeutics and prophylactics market.
- Drive revenues by understanding
the key trends, innovative products and technologies, market
segments, and companies likely to impact the CDI therapeutics and
prophylactics market in the future.
- Formulate effective sales and
marketing strategies by understanding the competitive landscape and
by analyzing the performance of various competitors.
- Identify emerging players with
potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Organize your sales and
marketing efforts by identifying the market categories and segments
that present maximum opportunities for consolidations, investments,
and strategic partnerships.
Send
An Enquiry Request @
https://www.marketresearchreports.biz/sample/enquiry/1350130
Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 9
2 Executive Summary 10
2.1 Significant Growth Is
Projected for the CDI Market from 2016 to 2026 10
2.2 Manufacturers Aiming to
Provide Physicians Non-Antibiotic Therapies for Treatment and
Prevention of CDI 12
2.3 There Remains Significant
Unmet Need for CDI Treatment, in Particular to Reduce CDI Recurrence
Rates 13
2.4 Opportunities Exist for
Products Proven to be Cost-Effective Versus SOC Antibiotics 14
2.5 An Active Pipeline Poised to
Partially Satisfy Unmet Needs for CDI 14
2.6 What do Physicians Think? 16
3 Introduction 18
3.1 Catalyst 18
3.2 Related Reports 18
3.3 Upcoming Related Reports 19
4 Disease Overview 20
4.1 Etiology and Pathophysiology
20
4.1.1 Etiology 20
4.1.2 Pathophysiology 24
4.2 Symptoms 26
4.3 Disease Management 27
4.3.1 Diagnosis 28
4.3.2 Treatment Guidelines 32
4.3.3 Clinical Practice 34
4.3.4 Prevention and Control 37
4.4 Prognosis and Quality of Life
39
5 Epidemiology 41
5.1 Disease Background 41
5.2 Risk Factors and Comorbidities
42
5.3 Global and Historical Trends
44
5.3.1 7MM: Diagnosed Incidence 45
5.3.2 7MM: Diagnosed Incident
Cases by Recurrence 46
5.3.3 7MM: Diagnosed Incident
Cases by Severity 47
5.4 Forecast Methodology 47
5.4.1 Sources 48
5.4.2 Forecast Assumptions and
Methods 51
5.5 Epidemiological Forecast for
CDI (2016-2026) 57
5.5.1 Diagnosed Incident Cases of
CDI 57
5.5.2 Age-Specific Diagnosed
Incident Cases of CDI 58
5.5.3 Sex-Specific Diagnosed
Incident Cases of CDI 58
5.5.4 CDI Cases by Recurrence 59
5.5.5 CDI Cases by Severity 61
5.6 Discussion 63
5.6.1 Epidemiological Forecast
Insight 63
5.6.2 Limitations of Analysis 65
5.6.3 Strengths of Analysis 65
6 Current Treatment Options 67
6.1 Overview 67
6.2 Product Profiles - Recommended
Antibiotic Therapies 68
6.2.1 Metronidazole (numerous
brand names) 68
6.2.2 Vancomycin (numerous brand
names) 73
6.2.3 Dificid (fidaxomicin) 78
6.3 Product Profiles - Antibodies
85
6.3.1 Zinplava (bezlotoxumab) 85
6.4 Other Antibiotic Therapies 90
6.4.1 Targocid (teicoplanin) 90
6.4.2 Tygacil (tigecycline) 91
6.4.3 Xifaxan (rifaximin) 92
6.5 Non-drug Interventions 92
6.5.1 OpenBiome FMT (stool-bank
service) 93
6.5.2 Probiotics 94
6.5.3 Surgical Procedures 95
About us
MarketResearchReports.biz is the
most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Comments
Post a Comment